Ignite Creation Date:
2025-12-24 @ 4:42 PM
Ignite Modification Date:
2026-02-03 @ 3:43 AM
Study NCT ID:
NCT03639766
Status:
TERMINATED
Last Update Posted:
2021-06-30
First Post:
2018-08-17
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon
Sponsor:
University of Central Florida
Organization:
Study Overview
Official Title:
The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon, a Double-Blind Randomized Placebo-Controlled Trial
Status:
TERMINATED
Status Verified Date:
2021-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Time and resource constraints
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to investigate the effect of abobotulinum toxin A on the symptoms of Raynaud's phenomenon.
Detailed Description:
This prospective double-blind randomized control trial seeks to compare a single formulation of BoNT, aboboutlinum toxin A (Dysport), to a placebo saline group, studying the effect of BoNT on Raynaud's symptoms among a more diverse population to provide insight into the patients most likely to benefit from BoNT.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?: